Tjoapack, a leading contract packaging organization serving the pharmaceutical industry, has announced a series of major investments across its USA and European operations to support the growing demand for biologic and injectable drug products. The company is expanding sterile packaging and cold chain storage capacity at its Clinton, Tennessee and Etten-Leur, Netherlands sites to improve speed, flexibility and supply chain resilience for clients across both regions.

At its site in Clinton, Tjoapack is nearing completion of two new packaging lines to enhance its sterile injectable services. A fully automated, high-speed vial packaging line, capable of handling up to 20 million vials annually, is being installed with integrated labeling, cartoning and serialization features. The line is currently undergoing commissioning and validation and is expected to be ready in the second quarter of 2025.

Alongside this, the company is adding a semi-automated packaging line dedicated to auto-injectors. This system will offer full traceability and labeling capabilities and is scheduled to be qualified in the third quarter of 2025.

In addition to its packaging capacity, Tjoapack has expanded cold storage space at its Clinton site to better support temperature-sensitive biologics. The new cold chain area is fully validated and offers 160 pallet spaces under controlled conditions of 2 to 8 degrees Celsius. These facilities are already operational and compliant with GMP regulations.

Similar improvements are taking place at the Etten-Leur site in the Netherlands. Tjoapack has added new validated cold storage space at 2 to 8 degrees Celsius. An additional 84 pallet spaces will be brought online in June 2025, increasing the site’s total cold chain capacity to 120 pallet positions.

The company has also successfully completed its first commercial project on a fully automated pre-filled syringe packaging line in Etten-Leur. The line is now operational and supporting new client programs, reflecting an increasing industry preference for patient-centric delivery formats. The system handles syringe assembly both with and without safety devices and is designed to automate key steps such as plunger rod insertion, safety device application, attachment of finger flanges and back-stops, and the addition of ancillary components such as needles.

“These upgrades directly address the accelerating needs of our clients in the biologics and sterile injectable space,” said Dexter Tjoa, CEO of Tjoapack. “We are committed to building scalable, compliant infrastructure that ensures the efficient delivery of vital therapies without compromising on flexibility or quality.”

Tjoapack’s expanded services now support a wide range of primary container formats, including vials, ampoules, syringes and auto-injectors. The company aims to increase capacity while ensuring quality and regulatory compliance across all operations. All cold storage areas are already validated and in use, while the new packaging lines are on track for GMP qualification in 2025.